Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Study of TTField Therapy (150 kHz) Versus Supportive Care in Non-small Cell Lung Cancer Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment

NCT01755624 is registered in ClinicalTrials.gov with NovoCure Ltd. as lead sponsor.

NCT NCT01755624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01755624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Study of TTField Therapy (150 kHz) Versus Supportive Care in Non-small Cell Lung Cancer Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment
Lead sponsor
NovoCure Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2013
Completion date
July 31, 2017
Enrollment
18 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

1-5 brain metastases from non-small cell lung cancer